Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Marker Therapeutics (NASDAQ: MRKR) announced CEO Dr. Juan Vera will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026, from 8:00–8:30 a.m. EST.

Rhea-AI Summary

Marker Therapeutics (NASDAQ: MRKR) announced CEO Dr. Juan Vera will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026, from 8:00–8:30 a.m. EST. The event is virtual; a webcast will be available via the company’s Investor Relations “Events and Presentations” page.

Management will hold one-on-one investor meetings to discuss progress across Marker’s Multi-Antigen Recognizing (MAR) T cell platform.

Argus Feb 18 session

+3.45% close to close Open Argus

Details

News Market Reaction – MRKR

In the Feb 18 session, MRKR gained 3.45%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights an upcoming investor conference appearance where management plans to di...

Analysis

This announcement highlights an upcoming investor conference appearance where management plans to discuss progress across its MAR T cell platform. In recent months, Marker has reported encouraging lymphoma and pancreatic cancer data and advanced MT-601 clinically, while operating at a market cap near $23.8M. Investors may monitor how the company frames clinical goals, funding strategy, and trial timelines during the February 25–26, 2026 event, and compare those messages with outcomes from prior clinical and financial updates.

Key Figures

Conference edition: 36th Conference dates: February 25-26, 2026 Presentation date: February 25, 2026 +2 more

Conference edition

36th

Oppenheimer Annual Healthcare Life Sciences Conference

Conference dates

February 25-26, 2026

Virtual Oppenheimer conference schedule

Presentation date

February 25, 2026

Marker’s scheduled conference presentation

Presentation time

8:00–8:30 a.m. EST

Marker’s conference presentation slot

Conference track

Track 3

Assigned track for Marker’s presentation

Historical Context

5 past events · Latest: Jan 26

5 events

1. Jan 26

   Clinical media coverage

   24h Move

   -10.9%

   Good Morning America feature on favorable Baylor pancreatic cancer MAR-T data.

2. Jan 05

   Clinical data update

   24h Move

   +16.2%

   Publication of Baylor pancreatic cancer study with 84.6% disease control rate.

3. Nov 14

   Earnings and updates

   24h Move

   +3.5%

   Q3 2025 results plus MT-601 APOLLO efficacy and funding via ATM.

4. Nov 05

   Board appointment

   24h Move

   +1.7%

   Appointment of experienced biopharma leader to strengthen board oversight.

5. Nov 03

   Conference presentations

   24h Move

   -2.9%

   Announcement of upcoming ASH presentations on MT-601 APOLLO Phase 1 data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

immuno-oncology, t cell-based immunotherapies, hematological malignancies, solid tumor indications, +1 more

5 terms

immuno-oncology medical

"a clinical-stage immuno-oncology company focusing on developing next-generation"

Immuno-oncology is a field of medicine focused on using the body's immune system to fight cancer. It involves developing treatments that help the immune system recognize and attack cancer cells more effectively. For investors, advancements in immuno-oncology can signal promising new therapies that may lead to improved patient outcomes and potentially significant commercial opportunities.

t cell-based immunotherapies medical

"developing next-generation T cell-based immunotherapies for the treatment of"

T cell-based immunotherapies are treatments that use a person’s immune cells—trained or changed in a lab—to hunt down and destroy diseased cells, such as cancer. For investors, they matter because successful therapies can command high prices and transform care like a new technology platform, but they also carry big risks from costly development, complex manufacturing, and regulatory or trial setbacks, making outcomes binary and value swings large.

hematological malignancies medical

"immunotherapies for the treatment of hematological malignancies and solid tumor"

Hematological malignancies are cancers that start in the blood-forming tissues or cells that circulate in the body, such as leukemia, lymphoma and multiple myeloma; think of them as harmful growths that disrupt the blood and immune systems rather than a single lump. Investors watch them because they define markets for drugs, diagnostics and treatments, influence clinical trial success and regulatory approval timelines, and can drive predictable long-term revenue or cost risks for healthcare companies.

solid tumor indications medical

"hematological malignancies and solid tumor indications, today announced that"

Solid tumor indications are types of cancers that form defined masses in tissues or organs (like breast, lung, liver or colon tumors) rather than cancers of the blood or bone marrow. For investors, they describe the specific medical uses a drug or therapy is being tested or approved for; think of them as the market segments a new treatment aims to hit, which affects potential patient numbers, regulatory hurdles and commercial value.

multi-antigen recognizing (mar) t cell platform medical

"progress across its Multi-Antigen Recognizing (MAR) T cell platform."

A multi-antigen recognizing (MAR) T cell platform is a therapy approach that engineers immune cells to detect and attack several distinct molecular targets on diseased cells rather than just one. Think of it as giving security guards several different descriptions of an intruder so they are less likely to miss or be fooled by changes; for investors this can mean broader patient reach, lower chances of the disease evading treatment, and potentially stronger commercial and regulatory value if safety and manufacturing scale are proven.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Executive Officer, Dr. Juan Vera, will present at the Oppenheimer 36^th Annual Healthcare Life Sciences Conference, being held in a virtual format on February 25-26, 2026.

Presentation Details:

Event:	Oppenheimer 36th Annual Healthcare Life Sciences Conference
Date:	Wednesday, February 25, 2026
Time:	8:00 – 8:30 a.m. EST
Track:	Track 3
Webcast Link:	“Events and Presentations” section on Marker’s IR website

During the conference, Dr. Vera and Marker’s management team will conduct one-on-one meetings with registered investors to discuss the Company’s progress across its Multi-Antigen Recognizing (MAR) T cell platform.

To view the event online, investors can register and access the webcast through Marker’s Investor Relations website under “Events and Presentations”.

About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a Houston, TX-based clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors. The Company was founded at Baylor College of Medicine, and clinical trials that enrolled more than 200 patients across various hematological and solid tumor indications showed that the Company’s autologous and allogeneic MAR-T cell products were well tolerated and demonstrated durable clinical responses. Marker’s goal is to introduce novel T cell therapies to the market and improve patient outcomes. To achieve these objectives, the Company prioritizes the preservation of financial resources and focuses on operational excellence. Marker’s unique T cell platform is strengthened by non-dilutive funding from U.S. state and federal agencies supporting cancer research.

To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts.

Forward-Looking Statements
This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi- antigen recognizing T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; and the timing, conduct, interim results and outcomes of our clinical trials of our product candidates, including MT-601 for the treatment of patients with lymphoma. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at WWW.SEC.GOV. The Company assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release except as may be required by law.

Investor and Media Contact
Marker Therapeutics, Inc.
+1 (713) 400-6400
investor.relations@markertherapeutics.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Marker Therapeutics (MRKR) present at the Oppenheimer conference in 2026?

Marker Therapeutics will present on Wednesday, February 25, 2026, 8:00–8:30 a.m. EST. According to the company, CEO Dr. Juan Vera will deliver the presentation and management will host one-on-one investor meetings during the virtual conference.

How can investors watch the MRKR presentation at the Oppenheimer 36th Annual Healthcare Life Sciences Conference?

Investors can view the webcast via Marker’s Investor Relations “Events and Presentations” page. According to the company, registration is required and the virtual webcast link will be posted on the IR site for attendees.

What topics will Marker Therapeutics (MRKR) discuss during the February 25, 2026 presentation?

Marker plans to discuss progress on its Multi-Antigen Recognizing (MAR) T cell platform and clinical updates. According to the company, CEO Dr. Juan Vera and management will review platform development and meet one-on-one with registered investors.

Who from Marker Therapeutics will present at the Oppenheimer healthcare conference for MRKR?

CEO Dr. Juan Vera will present, supported by Marker’s management team in investor meetings. According to the company, Dr. Vera will lead the session and management will hold one-on-one discussions with registered investors.

Is the Oppenheimer 36th Annual Healthcare Life Sciences Conference presentation by MRKR virtual or in-person?

The presentation is being held in a virtual format on February 25–26, 2026. According to the company, the MRKR session on February 25 will be webcast and accessible through the Investor Relations “Events and Presentations” section.

Will Marker Therapeutics (MRKR) offer investor meetings around the Oppenheimer conference presentation?

Yes, one-on-one meetings with management will be conducted for registered investors around the presentation. According to the company, these meetings will focus on the MAR T cell platform and the company’s clinical-stage progress.